
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New Orleans - Disorders that seemingly have no mycotic component could respond to a course of itraconazole (Sporanox), according to Ruggero Caputo, M.D. In fact, for certain patients, it may have a role in the treatment of inflammatory diseases such seborrheic dermatitis, atopic dermatitis, and rosacea, as well as palmo plantar amicrobic pustulosis.